Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Rym Lamrad

Hospitalist Minot, ND Medical Doctor

NPI 1497167852 CMS profile 5691567

2305 37Th Ave Sw, Minot, ND 58701

Open in the dashboard

General payments

$197

7 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Rym Lamrad of Minot, ND is reported in the CMS Open Payments database as having received $197 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $197 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rym Lamrad
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Rym Lamrad were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Rym Lamrad Hospitalist median Middle half National median
2019 $197 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $0 $85 $27–$174 $149
2023 $0 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program year 2019
  1. Novo Nordisk Inc $119 2 payments
  2. Amgen Inc. $37 2 payments
  3. Merck Sharp & Dohme Corporation $30 2 payments
  4. Novartis Pharmaceuticals Corporation $12 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $197 7 payments
Products named General payments · program year 2019
  1. Tresiba $115 1 payment
  2. Repatha $37 2 payments
  3. STEGLATRO $30 2 payments
  4. JANUVIA $30 2 payments
  5. JANUMET $30 2 payments
  6. AIMOVIG $20 1 payment
  7. Prolia $16 1 payment
  8. STEGLUJAN $15 1 payment
  9. JANUMET XR $15 1 payment
  10. ENTRESTO $12 1 payment
  11. Other $4 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

317

Median for Internal Medicine: 777

Drug cost

$7,075

Median for Internal Medicine: $73,373

Branded share of claims

17.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $4,406
Divalproex Sodium Generic 15 $428
Amiodarone Hcl Generic 12 $290
Levothyroxine Sodium Generic 31 $284
Metoprolol Succinate Generic 15 $234
Jantoven Warfarin Sodium Brand 33 $221
Atorvastatin Calcium Generic 37 $209
Furosemide Generic 41 $175
Potassium Chloride Generic 16 $151
Tamsulosin Hcl Generic 15 $134

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$33,368

Medicare's payments for the services billed

Medicare patients

197

Average age 78

Services billed

500

111 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 50%
Heart failure 49%
Diabetes 48%
Chronic kidney disease 48%
COPD 39%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record